Can Beam Keep Up With Sickle Cell Gene Therapy Frontrunners? Investors Are Unconvinced

Companies aiming to be fast followers in sickle cell disease gene therapy behind Vertex and bluebird have thinned out in 2023, and Beam may struggle to convince investors its base editing approach can compete.